Evidence map›Paper›PMID 40480912›Full record

Trial reportBritish journal of anaesthesia2025

Chemical ablation of pericapsular nerve group with 95% ethanol for pain relief and quality of life in patients with hip osteoarthritis: a prospective, double-blinded, randomised, controlled trial.

Małgorzata Reysner, Tomasz Reysner, Grzegorz Kowalski, Aleksander Mularski, Przemysław Daroszewski, Katarzyna Wieczorowska-Tobis

Registry-linked trialAbstract readClinical Trial, Phase IVRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06087588 (The Impact of the Pericapsular Nerve Group Block), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06087588 phase4completednot on this map

The Impact of the Pericapsular Nerve Group Block (PENG) Chemical Neurolysis on the Quality of Life of Patients with Advanced Hip Osteoarthritis. a Randomized, Prospective Double-blinded Clinical Trial.

TypeinterventionalSponsorPoznan University of Medical SciencesRan2023 to 2025Enrolled100ConditionsOsteoarthritis, Osteoarthritis, HipArms0.9%sodium chloride, 95% ethanol
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Phenol Neurolysis in Pain and Palliative Medicine.Pain practice : the official journal of World Institute of Pain · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Małgorzata ReysnerDepartment of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland. Electronic address: mdomagalska@ump.edu.pl.
Tomasz ReysnerDepartment of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Grzegorz KowalskiDepartment of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Aleksander MularskiDepartment of Forensic Medicine, Institute of Medical Sciences Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland.
Przemysław DaroszewskiDepartment of Organization and Management in Health Care, Poznan University of Medical Sciences, Poznan, Poland.
Katarzyna Wieczorowska-TobisDepartment of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic hip pain from osteoarthritis greatly diminishes quality of life, and standard treatments often fail to provide sufficient relief. Ultrasound-guided pericapsular nerve group (PENG) neurolysis using ethanol is a minimally invasive technique that may provide extended analgesia. This study evaluated the efficacy and safety of ultrasound-guided 95% ethanol neurolysis of the PENG compared with a sham procedure in patients with chronic hip pain.

methodsThis double-blinded, single-centre, RCT included 100 patients (median age: 82 yr [IQR 74-89]; 49% male) with chronic hip pain unresponsive to conservative treatments. Participants were assigned to either ethanol neurolysis (n=50) or a sham procedure (n=50). The primary outcome was pain intensity (numeric rating scale [NRS]) assessed at 7 days, 30 days, 3 months, and 6 months. Secondary outcomes included opioid consumption (oral morphine equivalents), quality of life (EQ-5D-5L), and neurological deficits.

resultsEthanol neurolysis significantly reduced NRS scores at all follow-ups (P<0.0001). The mean NRS scores decreased from baseline 6.0 (sd 0.9) to 3.1 (0.8) at 7 days, 2.9 (0.7) at 30 days, 2.8 (0.7) at 3 months, and 3.0 (0.7) at 6 months. Opioid consumption was lower in the neurolysis group at 7 days (median [IQR]: 1.5 [0.5-3.5] mg vs 11.5 [9.1-13.7] mg, P=0.002) and remained reduced through 6 months. Quality of life improved significantly (P<0.0001), and no neurological deficits were observed.

conclusionsUltrasound-guided ethanol neurolysis of the PENG is a safe and effective intervention for chronic hip pain, providing long-term relief and reducing opioid dependency. Further multicentre trials are needed to validate long-term outcomes. CLINICAL

trial registrationNCT06087588.

Indexed as

Chronic PainEthanolNerve BlockOsteoarthritis, HipPain ManagementQuality of LifeAgedAged, 80 and overDouble-Blind MethodFemaleHumansMalePain MeasurementProspective StudiesTreatment OutcomeUltrasonography, InterventionalEthanolchronic hip painethanol neurolysisopioid reductionosteoarthritisPENG blockultrasound-guided intervention

Identifiers

PMID40480912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.